Moreover, SGLT-2 inhibitors appear to have favorable consequences on NAFLD/NASH throughout mechanisms that are independent of weight and glucose, as it was shown in several studies. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.